Figure 9.

Inhibiting effect of the isolated Aloe polyketide constituents on the biosynthesis of the inflammation mediators LTB₄ and MDA in the above described in vitro test systems. Among these, only those that did display activity in at least one of the two test systems are depicted. All measurements were performed in triplicates at a concentration of 10 µM for all tested substances (for further details, see Materials and Methods). (A) aloin A/B (25.00% LTB₄ inhibition) (11 in Figure 1); (B) aloe emodin (15.00% LTB₄ inhibition) (10 in Figure 1); (C) 6′-O-(E)-coumaroyl-aloin A (32.00% LTB₄ inhibition) (12 in Figure 1); (D) 6′-O-(E)-coumaroyl-aloin B (41.00% LTB₄ inhibition) (13 in Figure 1); (E) 6′-O-(E)-coumaroyl-7-hydroxy-8-O-methyl-aloin B (22.00% LTB₄ inhibition) (15 in Figure 1); (F) aloesin (10.00% LTB₄ inhibition) (4 in Figure 1); (G) 3R-feralolide (24.00% MDA inhibition) (1 in Figure 1).